Quantcast

Latest Torcetrapib Stories

2011-05-04 06:15:00

HOERSHOLM, Denmark and SAN DIEGO, May 4, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced SPC5001 into Phase 1 clinical trials for the treatment of high cholesterol. SPC5001 is a mRNA-targeted drug that inhibits the exciting new target, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), a protein involved in removing low density...

2010-05-26 09:58:35

HDL cholesterol can transform from good to bad actor in heart disease process We've all heard about the importance of raising HDL, or the so-called "good" cholesterol, and lowering LDL, or "bad" cholesterol, to improve heart health. While we've come to assume HDL cholesterol is an inherently good thing, a new study shows that for a certain group of patients, this is not always the case. The study is the first to find that a high level of the supposedly good cholesterol places a subgroup of...

2010-01-25 07:00:00

WALTHAM, Mass., Jan. 25 /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of dyslipidemia, the rapid uptake of Roche/Japan Tobacco's first-in-class dalcetrapib and Merck's anacetrapib will drive $3.2 billion in sales of the cholesteryl ester transfer protein (CETP) inhibitors drug class in 2018 in the world's major pharmaceutical markets. Anacetrapib and dalcetrapib appear to...

2009-12-15 23:19:28

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests. Scientists at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University  and Boston University School of Medicine found an association between low plasma cholesterol ester transfer protein (CETP) activity and increased risk of heart disease in the...

2008-12-05 08:56:01

If you're not one of the 17 percent of Americans who have high cholesterol, you may consider yourself healthy overall. New research that shows some good cholesterol can negatively affect your health may change your mind.Conventional wisdom says having high levels of good cholesterol, or HDL, and low levels of bad cholesterol, or LDL, plays a large role in keeping you healthy. A recent study challenges that idea. After reviewing published data on the topic of good versus bad cholesterol,...

2008-11-14 09:00:06

Pfizer has reported positive findings from a post hoc sub-analysis of the five-year Treating to New Targets study. According to the company, improvements in kidney function in patients treated with Lipitor were shown to strongly correlate with a reduced risk of major cardiovascular events in patients with pre-existing cardiovascular disease. In this new post hoc analysis, kidney function was assessed using estimated glomerular filtration rate (eGFR), as recommended by the National Kidney...

2008-09-25 12:00:15

Anthera Pharmaceuticals has reached an agreement with the FDA on a Phase III protocol for varespladib in acute coronary syndrome under the FDA's special protocol assessment procedure. At the same time, the company has received scientific advice from the European Medicines Agency (EMEA) on Anthera's European development strategy for varespladib. Anthera has said that the guidance from both regulatory agencies regarding varespladib will be incorporated into the company's global registration...

2008-09-03 06:00:06

By Alex Berenson When the U.S. Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that the treatment had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug. The lack of evidence has not stopped doctors from heavily prescribing that...

2006-08-09 18:10:27

By Gene Emery BOSTON (Reuters) - Patients who take Lipitor, a drug used to treat heart patients, are less likely to suffer a second stroke, according to a study paid for by the drug's maker, Pfizer Inc. The research, published in this week's New England Journal of Medicine, found that the drug, one of a class of cholesterol fighting drugs known as statins, cut the overall risk of another stroke by about 16 percent over five years. Stroke is the third largest cause of death in the...

2006-07-26 01:20:00

NEW YORK -- Pfizer Inc. will apply for approval to sell a new heart treatment as a single pill, rather than only in combination with its top selling Lipitor, the New York Times reported on Wednesday, quoting a company executive. The new drug, torcetrapib, is still being tested in clinical trials and is at least 18 months from federal approval, but cardiologists say it has potential to become a significant new treatment for heart disease, the report said. Dr. Joseph Feczko, Pfizer's chief...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related